Progressive Supranuclear Palsy vs Alzheimer's Disease: sAPPβ (CSF)


Back to the Top

Meta-analysis of three studies suggests that the level of sAPPβ in cerebrospinal fluid of people with progressive supranuclear palsy is lower than that of people with Alzheimer's disease (effect size = 0.704), although the p value (0.009) is marginally significant. For comparison, levels of sAPPβ in CSF were similar in control subjects and AD patients. A meta-analysis comparing PSP patients to control subjects reported that sAPPβ levels are lower in patients (Tang et al., 2020).

Loading data...

How to interpret a forest plot: Each individual effect size (ES) is a ratio of the mean biomarker level in one condition over the mean level in another condition. An ES equal to 1 means that the two conditions had identical mean values. An ES > 1 indicates higher levels in the first condition, whereas an ES < 1 indicates lower levels in the first condition. The overall ES, indicated by a black diamond, is a weighted average of the individual effect sizes. The weight of each data point was determined by the inverse of the variance and is reflected in the size of each square. The width of the overall ES diamond is determined by the 95 percent confidence interval. Data out of range of the scale, including ES and confidence intervals, are indicated by an arrowhead at the edge of the plot, when applicable. 

Version 3.0, July 2021.